AstraZeneca acquired Amolyt Pharma, a Cambridge, MA- and Lyon, France-based clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, for up to $1.05 Billion.
The purchase price was $800m upfront and a potential milestone payment of $250m. Alexion, AstraZeneca Rare Disease, is adding the team from Amolyt Pharma.
The transaction is expected to close in the third quarter of 2024.
Amolyt’s clinical pipeline includes differentiated therapeutic peptides for the treatment of underserved rare endocrine disease. Eneboparatide (AZP-3601) is an investigational daily subcutaneous injectable parathyroid hormone receptor 1 (PTHR1) agonist for the treatment of hypoparathyroidism, that is currently in Phase 3. AZP-3813 is a peptide growth hormone receptor antagonist for the potential treatment of acromegaly that is in Phase 1.
Commenting on the news, Thierry Abribat, Ph.D., CEO and Founder of Amolyt Pharma, said: “We are proud of the remarkable achievements of our team in building and developing a portfolio of therapeutic peptides with the potential to address significant unmet needs for rare endocrine and related diseases, having advanced eneboparatide to Phase 3 for hypoparathyroidism and created an early-stage pipeline in less than 5 years. We are grateful to the investigators, patients, and patient associations who have supported us to reach these goals.”
FinSMEs
14/02/2024